A trial of heat therapy plus immunotherapy for HER2-negative breast cancer with liver spread
Treatments studied
Part of Cancer clinical trials.
This study tests combining a special heat treatment (thermal therapy) with immunotherapy to see if it works better for HER2-negative breast cancer that has spread to the liver. It may help people who have already tried other treatments and whose cancer has gotten worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- Your breast cancer must be HER2-negative and has spread to the liver.
- You must have already tried at least one cancer treatment (like hormone therapy or chemo) and it stopped working.
- You must have tumors in the liver that are no larger than 4 cm and no more than 10 in number.
- You must be willing to use effective birth control during and for 3 months after treatment if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies an immune-based treatment for women with HR-positive and HER2-negative breast cancer that has spread or returned and can’t be cured with local treatment alone. The goal is to see whether the therapy can shrink tumors and improve disease control with acceptable safety.
This trial tests a new treatment that uses heat to target liver tumors and boost the immune system. It is for women with breast cancer that has spread to the liver who cannot have or do not want surgery.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests a new drug (SHR-1826) alone or with immunotherapy for people with advanced liver cancer that has not responded to at least one prior treatment. It aims to see if the treatment can shrink tumors or slow the cancer's growth.
This study tests two ways to treat HER2-positive breast cancer before surgery: one uses a single drug (SHR-A1811), and the other uses that drug followed by a combination (THPy). The goal is to see which approach works better at shrinking tumors before surgery.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.